Commerzbank Aktiengesellschaft FI reduced its stake in Bristol-Myers Squibb Co (NYSE:BMY) by 1.5% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 541,056 shares of the biopharmaceutical company’s stock after selling 8,501 shares during the quarter. Commerzbank Aktiengesellschaft FI’s holdings in Bristol-Myers Squibb were worth $33,156,000 at the end of the most recent quarter.
Several other large investors also recently modified their holdings of BMY. Atlantic Trust LLC purchased a new stake in shares of Bristol-Myers Squibb in the second quarter valued at $111,000. Massey Quick Simon & CO. LLC increased its stake in Bristol-Myers Squibb by 523.5% in the third quarter. Massey Quick Simon & CO. LLC now owns 1,777 shares of the biopharmaceutical company’s stock valued at $113,000 after purchasing an additional 1,492 shares during the last quarter. Blue Chip Partners Inc. increased its stake in Bristol-Myers Squibb by 0.7% in the second quarter. Blue Chip Partners Inc. now owns 2,156 shares of the biopharmaceutical company’s stock valued at $120,000 after purchasing an additional 15 shares during the last quarter. Horan Capital Advisors LLC. acquired a new position in Bristol-Myers Squibb in the third quarter valued at $122,000. Finally, BDO Wealth Advisors LLC acquired a new position in Bristol-Myers Squibb in the second quarter valued at $123,000. Institutional investors and hedge funds own 69.82% of the company’s stock.
In other news, Director Theodore R. Samuels II purchased 4,000 shares of the company’s stock in a transaction on Friday, December 15th. The stock was bought at an average cost of $62.30 per share, for a total transaction of $249,200.00. Following the completion of the purchase, the director now directly owns 22,000 shares of the company’s stock, valued at approximately $1,370,600. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Sandra Leung sold 156,582 shares of the company’s stock in a transaction dated Monday, December 4th. The stock was sold at an average price of $63.37, for a total value of $9,922,601.34. Following the completion of the sale, the executive vice president now directly owns 584,373 shares of the company’s stock, valued at approximately $37,031,717.01. The disclosure for this sale can be found here. Corporate insiders own 0.23% of the company’s stock.
Shares of Bristol-Myers Squibb Co (NYSE:BMY) opened at $67.95 on Friday. The company has a market capitalization of $111,210.00, a PE ratio of 28.79, a price-to-earnings-growth ratio of 2.07 and a beta of 1.08. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.43 and a current ratio of 1.55. Bristol-Myers Squibb Co has a 12 month low of $51.56 and a 12 month high of $70.05.
Bristol-Myers Squibb (NYSE:BMY) last announced its quarterly earnings results on Monday, February 5th. The biopharmaceutical company reported $0.68 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.67 by $0.01. The company had revenue of $5.45 billion during the quarter, compared to analyst estimates of $5.35 billion. Bristol-Myers Squibb had a return on equity of 35.43% and a net margin of 4.85%. The firm’s revenue was up 3.9% on a year-over-year basis. During the same period in the prior year, the firm posted $0.63 earnings per share. sell-side analysts anticipate that Bristol-Myers Squibb Co will post 3.21 EPS for the current fiscal year.
The company also recently declared a quarterly dividend, which was paid on Thursday, February 1st. Shareholders of record on Friday, January 5th were paid a dividend of $0.40 per share. The ex-dividend date of this dividend was Thursday, January 4th. This is a positive change from Bristol-Myers Squibb’s previous quarterly dividend of $0.39. This represents a $1.60 annualized dividend and a yield of 2.35%. Bristol-Myers Squibb’s dividend payout ratio is currently 67.80%.
Several equities analysts recently commented on BMY shares. Zacks Investment Research lowered Bristol-Myers Squibb from a “hold” rating to a “sell” rating in a research note on Tuesday, January 9th. Vetr lowered Bristol-Myers Squibb from a “hold” rating to a “sell” rating and set a $59.70 target price for the company. in a research note on Thursday, December 28th. SunTrust Banks upgraded Bristol-Myers Squibb from a “hold” rating to a “buy” rating in a research note on Monday, October 30th. BMO Capital Markets reiterated a “sell” rating and issued a $52.00 target price on shares of Bristol-Myers Squibb in a research note on Monday, January 22nd. Finally, Citigroup set a $72.00 target price on Bristol-Myers Squibb and gave the company a “buy” rating in a research note on Tuesday, December 5th. Three research analysts have rated the stock with a sell rating, eight have assigned a hold rating and eight have given a buy rating to the company. The company has a consensus rating of “Hold” and a consensus price target of $66.18.
Bristol-Myers Squibb Company Profile
Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.
Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Co (NYSE:BMY).
Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.